期刊文献+

CP化疗方案对卵巢癌患者血清IL-2及CA125含量的影响 被引量:2

The Effects of CP Chemotherapy Regimen on the Serum IL-2 and CA125 Levels in Patients with Ovarian Cancer
下载PDF
导出
摘要 目的探讨CP化疗方案对卵巢癌患者血清IL-2及CA125水平的影响。方法将2009年10月~2011年6月在本院接受CP方案化疗的38例卵巢癌患者作为研究对象,并以同期在本院进行体检的40例健康女性作为对照,采用酶联免疫吸附法(ELISA)检测受试者血清中的IL-2及CA125的含量。结果化疗前,卵巢癌患者血清中IL-2含量显著低于对照组,CA125含量显著高于对照组(P<0.05);而化疗后,卵巢癌患者血清中IL-2含量较化疗前显著升高,CA125含量较对照组显著降低,两者与对照组比较均无统计学差异(P>0.05)。CP化疗方案治疗卵巢癌的有效率为96.4%,且疗效与患者血清IL-2及CA125水平显著相关,治疗效果越好,血清中IL-2水平越高,血清CA125水平越低。结论 CP化疗方案治疗卵巢癌患者的效果较好,可能与影响患者血清IL-2及CA125的水平有关。 Objective To investigate the effects of CP chemotherapy regimen on the serum IL-2 and CA125 levels in patients with ovarian cancer. Methods 38 cases of patients with ovarian cancer who were treated by CP chemotherapy regi- mens from October 2009 to June 2011 in our hospital were selected as research group, and 40 cases of healthy people ex- amined in our hospital at the same time were chosen as the control group, the serum IL-2 and CA125 levels of two groups were detected by using enzyme-linked immunosorbent method (ELISA). Results Before Chemotherapy, the serum IL-2 content of ovarian cancer patients was significantly lower than that in the control group, but the serum CA125 content was significantly higher(P 〈 0.05). After chemotherapy, the serum IL-2 content of ovarian cancer patients was significandy higher than that before treatment, while the serum CA125 content was significantly lower than that before treatment(P〈 0.05). No significant difference was observed in serum CA125 and IL-2 content between the two groups after chemotherapy (P〉 0.05). The total effective rate of CP chemotherapy on the ovarian cancer was 96.4%, which was significantly related to the serum IL-2 and CA125 levels. The better efficacy, the higher the serum IL-2 level was and the lower serum CA125 level. Conclusion CP chemotherapy was effective in the treatment of ovarian cancer. The serum IL-2 and CA125 level may be involved in the efficacy of CP chemotherapy.
出处 《肿瘤药学》 CAS 2012年第6期439-442,共4页 Anti-Tumor Pharmacy
关键词 卵巢癌 IL-2 CA125 化疗 Ovarian cancer IL-2 CA125 Chemotherapy
  • 引文网络
  • 相关文献

参考文献19

二级参考文献148

共引文献329

同被引文献23

  • 1曲延峻,韩燕燕,耿红光,宫丽华.56例卵巢上皮性交界性肿瘤的临床和病理分析[J].生物磁学,2006,6(1):39-40. 被引量:5
  • 2Sirnon I,Liu Y,Krall KL. Evaluation of the novel serum markers B7-H4,Spondin 2,and DcR3 for diagnosis and early detection of ovarian cancer[J].{H}Gynecologic Oncology,2007,(01):112-118.
  • 3Bingle L,Singleton V,Bingle CD. The putative ovarian tu-mor maker gene HE4(WFDC2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms[J].{H}ONCOGENE,2002,(17):2768-2773.
  • 4Galgano MT,Hampton GM,Frierson HF Jr. Compre-hensive analysis of HE4 expression in normal and malignant human tissues[J].{H}Modern Pathology,2006,(06):847-853.
  • 5Cohen LS,Escobar PF,Scharrn C. Three-dimen-sional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction[J].{H}Gynecologic Oncology,2001,(01):40-48.
  • 6Krambeck AE,Thompson RH,Dong H. B7-H4 expreasion in renal cell carcinoma and tumor vasculature:associations with eancer progression and survival[J].{H}Proceedings of the National Academy of Sciences(USA),2006,(27):10391-10396.
  • 7连利娟;胡秀风;刘文淑.卵巢癌单克隆抗体在诊断上的应用[J]{H}中华妇产科杂志,1985(05):257.
  • 8Miyatake T,Tringler B,Liu W. B7-H4(DD-0110) is overexpressed in high risk uterine eadometrioid adeno-carcinomas and inversely correlated with tumor T-cell infiltration[J].{H}Gynecologic Oncology,2007,(01):119-127.
  • 9Sica GL,Choi IH,Zhu G. B7-H4,a molecule of the B7 family negatively regulates T cell immunity[J].Immu-nity,2003,(06):849-861.
  • 10Salceda S,Tang T,Kmet M. The immunomodula-tory protein B7-H4 is overexpreased in breast and ovarian cancers and promotes epithellal cell transformation[J].{H}Experimental Cell Research,2005,(01):128-141.

引证文献2

二级引证文献12

;
使用帮助 返回顶部